Compare Marriott International Inc (MAR) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Marriott International Inc trades at $360.95 (market cap $92.96B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Marriott International Inc is far larger — about 3.7× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| MAR | RPRX | |
|---|---|---|
Market Cap | $92.96B | $25.27B |
Volume | 1,173,633 | 3,671,183 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $63.96 |
52-Week Low | $259.04 | $35.44 |
Typical Hold Time | 164 Days | 0 Days |
Enterprise Value | $110.28B | $32.50B |
Dividend Yield | 0.82% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $361.08, showing minimal daily movement with a slight decline of 0.06%. The stock maintains a bullish technical signal with strong moving average support and trades near key resistance at $360. Fundamentally, the company reported solid Q2 2026 earnings beat with $3.19 EPS versus $3.08 expected, continuing revenue growth to $26.19B in 2025, though valuation ratios remain elevated with P/E at 36.9. Recent developments include new technology partnerships and upcoming dividend payment.
Marriott presents a mixed investment case with strong operational performance offset by high valuation multiples. The consensus price target of $386.71 suggests 7% upside potential, supported by 44% analyst buy ratings. Key risks include rising debt levels with debt-to-asset ratio reaching 58.83% and potential travel sector volatility. The company's dominant market position and continued travel demand provide growth catalysts, but investors should weigh valuation concerns against fundamental strength.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
